海曲泊帕治疗生殖细胞肿瘤治疗后血小板减少症的临床疗效分析

doi:10.3969/j.issn.1006-7795.2025.03.004

首都医科大学学报 ›› 2025, Vol. 46 ›› Issue (3): 420-426.doi: 10.3969/j.issn.1006-7795.2025.03.004

• 肿瘤研究进展：从基础到临床 • 上一篇下一篇

海曲泊帕治疗生殖细胞肿瘤治疗后血小板减少症的临床疗效分析

李亚伟¹,杨守博²,尹硕²,李文斌²,陈峰^2*

1.贵阳市第二人民医院肿瘤科，贵州贵阳 550000；2.首都医科大学附属北京天坛医院肿瘤综合治疗中心神经肿瘤综合治疗病区，北京 100070

收稿日期:2025-02-27 出版日期:2025-06-21 发布日期:2025-06-24
通讯作者: 陈峰 E-mail:chenfeng406@sina .com
基金资助:
国家重点研发计划项目(2021YFF0901404)。

Clinical efficacy analysis of hetrombopag in the treatment of cancer therapy included thrombocytopenia for germ cell tumors

Li Yawei¹, Yang Shoubo², Yin Shuo², Li Wenbin², Chen Feng^2*

1.Department of Oncology, The Second People's Hospital of Guiyang City, Guiyang 550000, Guizhou Province, China; 2. Department of Neuro-oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China

Received:2025-02-27 Online:2025-06-21 Published:2025-06-24
Supported by:
This study was supported by the National Key Research & Development Program of China (2021YFF0901404).

摘要/Abstract

摘要： 目的分析联合海曲泊帕治疗生殖细胞肿瘤治疗后血小板减少症（cancer therapy induced thrombocytopenia，CTIT) 的疗效及安全性。方法收集并分析2021年1月至2024年3月收治的颅内生殖细胞肿瘤化学药物治疗（以下简称化疗）后合并CTIT≥Ⅲ级患者的资料，筛选符合入组标准的患者33例，其中研究组为口服海曲泊帕联合皮下注射重组人血小板生成素（recombinant human thrombopoietin, rhTPO）或白细胞介素-11（interleukin-11, IL-11）治疗，对照组为皮下注射rhTPO或IL-11，对比两组患者治疗前后血小板计数、升血小板应答率、平均起效时间、下一周期治疗延长发生率的差异，并统计两组不良反应。结果两组患者在接受上述治疗后，血小板计数均有提高，用药后第1、2、3天血小板计数升高两组之间差异无统计学意义（P>0.05），研究组用药后第(7±3)天血小板升高计数对比对照组有显著升高，差异有统计学意义（P<0.05)，随着时间延长升血小板应答率有所升高。研究组用药平均起效时间3（3，5）d，对照组平均起效时间为4（3，7）d，差异无统计学意义（P>0.05）。研究组导致下一周期治疗时间延长发生率为54.5%，对照组下一周期治疗时间延长发生率为81.8%，两组之间差异无统计学意义（P>0.05）。研究组有2名患者出现轻度可逆性肝功能异常。结论海曲泊帕联合rhTPO或IL-11治疗颅内生殖细胞肿瘤化疗后CTIT症的疗效可靠，可显著提升血小板计数，不良反应可耐受。

关键词: 海曲泊帕, 颅内生殖细胞肿瘤, 肿瘤治疗后血小板减少症, 重组人血小板生成素, 白细胞介素-11

Abstract: Objective To retrospectively analyze the efficacy and safety of combined hetrombopag in the treatment of cancer therapy induced thrombocytopenia （CTIT） after chemotherapy for germ cell tumors. Methods The data of patients with CTIT ≥ grade Ⅲ combined with chemotherapy for intracranial germ cell tumors admitted from January 2021 to March 2024 were collected and analyzed, and 33 patients met the enrollment criteria. The patients in the study group were treated with oral hetrombopag combined with subcutaneous injections of recombinant human thrombopoietin (rhTPO) or interleukin-11 (IL-11), and those in the control group were treated with subcutaneous injections of rhTPO or IL-11. The differences of the two groups of patients in platelet counts, platelet-raising response rate, mean onset of action time, and prolongation of the next cycle of treatment before and after the treatment were compared to each other, and the adverse reactions of the two groups were also counted. Results The platelet counts of patients in both groups were improved post-treatment, with no statistical significance between the two groups for platelet count elevation on days d1, d2, and d3 of the medication (P>0.05). The platelet elevation counts of the study group were significantly elevated on day d(7 ± 3) after the medication compared with the control group, with a statistically significant difference (P<0.05), and the rate of platelet elevation response increased with time prolongation. The mean time to onset of drug administration was 3（3，5） in the study group and 4（3，7）in the control group, with no statistically significant difference (P>0.05). The incidence of prolongation of the time to the next cycle of treatment was 54.5% in the study group and 81.8% in the control group, and the difference between the two groups was not statistically significant (P>0.05). Two patients in the study group developed mild reversible liver function abnormalities. Conclusion The efficacy of hetrombopag combined with subcutaneous injection of t rhTPO or IL-11 in the treatment of thrombocytopenia after chemotherapy for intracranial germ cell tumors is reliable, and it can significantly elevate platelet counts with tolerable adverse effects.

Key words: hetrombopag, intracranial germ cell tumors, cancer therapy induced thrombocytopenia, recombinant human thrombopoietin, interleukin-11.

中图分类号:

R730.6

李亚伟, 杨守博, 尹硕, 李文斌, 陈峰. 海曲泊帕治疗生殖细胞肿瘤治疗后血小板减少症的临床疗效分析[J]. 首都医科大学学报, 2025, 46(3): 420-426.

Li Yawei, Yang Shoubo, Yin Shuo, Li Wenbin, Chen Feng. Clinical efficacy analysis of hetrombopag in the treatment of cancer therapy included thrombocytopenia for germ cell tumors[J]. Journal of Capital Medical University, 2025, 46(3): 420-426.

参考文献

［1］Price M, Neff C, Nagarajan N, et al. CBTRUS statistical report: American brain tumor association & NCI neuro-oncology branch adolescent and young adult primary brain and other central nervous system tumors diagnosed in the United States in 2016－2020［J］. Neuro Oncol, 2024, 26(3): iii1－iii53.
［2］Frappaz D, Dhall G, Murray M J, et al. EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults［J］. Neuro Oncol, 2022, 24(4): 516－527.
［3］史艳侠,邢镨元,张俊等.中国肿瘤化疗相关性血小板减少症专家诊疗共识(2019版)［J］. 中国肿瘤临床, 2019, (18): 923－929.
［4］Zhou D, Zhang Y, Liu H, et al. Epidemiology of nervous system tumors in children: a survey of 1,485 cases in Beijing Tiantan Hospital from 2001 to 2005［J］. Pediatric Neurosurgery, 2008, 44(2): 97－103.
［5］Gittleman H, Cioffi G, Vecchione-koval T, et al. Descriptive epidemiology of germ cell tumors of the central nervous system diagnosed in the United States from 2006 to 2015［J］. J Neurooncol, 2019, 143(2): 252－260.
［6］McNamara C, Mankad K, Thust S, et al. 2021 WHO classification of tumours of the central nervous system: a review for the neuroradiologist［J］. Neuroradiology, 2022, 64(10): 1919－1950.
［7］中国抗癌协会肿瘤支持治疗专业委员会. 中国肿瘤药物相关血小板减少诊疗专家共识(2023版)［J］. 中华医学杂志, 2023, 103(33): 2579－2590.
［8］王圆,杜淑旭,孙艳玲等.重组人血小板生成素皮下注射对脑肿瘤化疗患儿血小板减少症的预防效果［J］.山东医药, 2021, 61(36): 48－50.
［9］王增,陈岷,苏晓华.循证药学在处理抗肿瘤药物不良反应中的应用实例［J］. 药物流行病学杂志, 2017, 26(2): 137－142.
［10］Al-Samkari H, Kolb-Sielecki J, Safina S Z, et al. Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial［J］. Lancet Haematol, 2022, 9(3): e179－e189.
［11］Gurumurthy G, Kisiel F,Gurumurthy S ,et al. Role of thrombopoietin receptor agonists in chemotherapy-induced thrombocytopenia: a meta-analysis［J］. J Oncol Pharm Pract, 2025, 31(1): 4－11.
［12］梅婷, 孙小力,齐淑静,等. 自拟益气健脾解毒化瘀方联合艾曲泊帕治疗恶性肿瘤化疗相关性血小板减少症的临床效果［J］. 临床误诊误治, 2023, 36 (6): 138-142.
［13］张美玲, 潘家东,张东伟. 阿伐曲泊帕联合升血饮、硒酵母预防肿瘤化疗所致血小板减少症的随机对照临床研究［J］. 实用临床医药杂志, 2023, 27 (4): 104-107,112.
［14］Wilkins C R, Ortiz J, Gilbert L J, et al. Romiplostim for chemotherapy-induced thrombocytopenia: efficacy and safety of extended use［J］. Res Pract Thromb Haemost, 2022, 6(3): e12701.
［15］徐慧,赵洋,马雅婷等.阿伐曲泊帕与重组人血小板生成素治疗肿瘤化疗所致血小板减少症的疗效及安全性［J］. 中华实用诊断与治疗杂志, 2022, 36(10): 1073－1076.
［16］李红梅, 余文熙, 彭志刚等. 阿伐曲泊帕治疗肿瘤化疗所致血小板减少症的疗效及安全性的回顾性研究［J］. 肿瘤, 2021, 41(12): 832－839.
［17］Lozano M L, Rodeghiero F. Thrombopoietin receptor agonist in chemotherapy-induced thrombocytopenia［J］.Lancet Haematol, 2022, 9(3): e168－e169.
［18］Peng G, He G, Chang H, et al. A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy［J］. Ther Adv Hematol, 2022, 13:20406207221085197.
［19］Xie C, Zhao H, Bao X, et al. Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist［J］. J Cell Mol Med, 2018, 22(11): 5367－5377.
［20］Zheng L, Liang M Z, Zeng X L,et al.Safety, pharmacokinetics and pharmacodynamics of hetrombopag olamine, a novel TPO-R agonist, in healthy individuals［J］.Basic Clin Pharmacol Toxicol, 2017, 121(5): 414－422.
［21］Gilreath J, Lo M, Bubalo J.Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists［J］. Drugs, 2021, 81(11): 1285－1305.
［22］李杰,华云旗,谭亚琴等. 海曲泊帕治疗实体瘤化疗后血小板Ⅲ,Ⅳ度患者的临床疗效分析［J］. 中国现代医学杂志, 2024, 34(20): 57－61.
［23］莫峥,于飞,李利红等.海曲泊帕治疗实体瘤化疗所致血小板减少症效果观察［J］. 肿瘤研究与临床, 2023, 35(9): 703－705.
［24］杨婧,严冬,仝营营等.海曲泊帕联合重组人血小板生成素治疗抗肿瘤治疗所致血小板减少症的回顾性队列研究［J］. 临床血液学杂志, 2024, 37(11): 794－798.
［25］张馨月,刘倩,洪誉鹏,等.肿瘤治疗相关血小板减少症的治疗:海曲泊帕联合特比澳的病例系列和文献综述［J］. 临床医学进展, 2024, 14(4): 2477－2485.

海曲泊帕治疗生殖细胞肿瘤治疗后血小板减少症的临床疗效分析

Clinical efficacy analysis of hetrombopag in the treatment of cancer therapy included thrombocytopenia for germ cell tumors

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics

本文评价